Literature DB >> 8497624

Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.

L P Adler1, J P Crowe, N K al-Kaisi, J L Sunshine.   

Abstract

Twenty-eight patients with a total of 35 suspect breast masses underwent positron emission tomography (PET) with [fluorine-18] 2-deoxy-2-fluoro-D-glucose (FDG) in order to study the utility of this technique in the evaluation of breast cancer. FDG PET allowed discrimination between eight benign and 27 malignant breast masses, with a sensitivity of 96% and specificity of 100%. Among the malignancies, there was a significant correlation between normalized FDG uptake and nuclear grade (P = .006). In addition, the results of PET imaging were compared with results of axillary node dissection in 20 cases of breast cancer. PET allowed correct categorization of 10 of 10 axillae as negative (specificity = 100%). PET results were equivocal in one axilla and positive in the remaining nine of 10 axillae with positive dissection results (sensitivity = 90%). The authors conclude that FDG PET may give useful information on breast masses and axillary node status prior to surgery.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8497624     DOI: 10.1148/radiology.187.3.8497624

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  43 in total

1.  MR imaging-guided axillary node biopsy for breast cancer: initial findings.

Authors:  Takuji Yamagami; Sachiko Yuen; Kiyoshi Sawai; Tsunehiko Nishimura
Journal:  Eur Radiol       Date:  2003-06-14       Impact factor: 5.315

Review 2.  PET/CT and breast cancer.

Authors:  Barbara Zangheri; Cristina Messa; Maria Picchio; Luigi Gianolli; Claudio Landoni; Ferruccio Fazio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-05       Impact factor: 9.236

3.  Oncologic positron emission tomography: a surgical perspective.

Authors:  Todd O Moore; Landis K Griffeth
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

4.  Intramuscular diffuse-type giant cell tumor within the hamstring muscle.

Authors:  Tatsuya Yoshida; Akio Sakamoto; Kazuhiro Tanaka; Yukihide Iwamoto; Yoshinao Oda; Teiyu Izumi; Masazumi Tsuneyoshi
Journal:  Skeletal Radiol       Date:  2006-07-19       Impact factor: 2.199

5.  Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.

Authors:  Nanda C Krak; Jacobus J M van der Hoeven; Otto S Hoekstra; Jos W R Twisk; Elsken van der Wall; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-15       Impact factor: 9.236

6.  Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.

Authors:  I C Smith; K N Ogston; P Whitford; F W Smith; P Sharp; M Norton; I D Miller; A K Ah-See; S D Heys; J A Jibril; O Eremin
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

Review 7.  Advantages and limitations of FDG PET in the follow-up of breast cancer.

Authors:  Peter Lind; Isabel Igerc; Thomas Beyer; Peter Reinprecht; Klaus Hausegger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-15       Impact factor: 9.236

8.  Application of whole-body positron emission tomography in the imaging of esophageal cancer: report of a case.

Authors:  S Yasuda; S Raja; K F Hubner
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

9.  Follow-up of women with breast cancer: comparison between MRI and FDG PET.

Authors:  Gerhard W Goerres; Sven C A Michel; Mathias K Fehr; Achim H Kaim; Hans C Steinert; Burkhardt Seifert; Gustav K von Schulthess; Rahel A Kubik-Huch
Journal:  Eur Radiol       Date:  2002-11-13       Impact factor: 5.315

Review 10.  Current role of positron emission tomography in thoracic oncology.

Authors:  V J Lowe; K S Naunheim
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.